Short answer
ALUMIS INC. (ALMS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M (down 7.7% year over year) with net income of −$95M.
Q3 2026 key financials · XBRL
- Revenue
- $2M
- −7.7% YoY · +14.7% QoQ
- Net income
- −$95M
- +14.3% YoY · +33.3% QoQ
- Operating margin
- -5195.4%
- EPS (diluted)
- −$0.73
- +44.3% YoY · +34.8% QoQ
Source: XBRL data from the ALUMIS INC. (ALMS) Q3 2026 10-Q on SEC EDGAR. USD.
ALUMIS INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.9M, down 8% YoY from $2.1M, entirely collaboration revenue
- Net loss $94.9M vs $110.8M YoY, operating loss $99.1M vs $115.3M
- Envu, best-performing program: external R&D costs $42.0M vs $48.9M YoY
- Operating cash use $248.2M for nine months, down from $297.6M; financing provided $367.2M
- Cash, equivalents and marketable securities $431.3M, insufficient for 12 months; NDA submission planned by end of 2026
Risk Factors
- Newly highlighted trade risk: 10% baseline tariff and Section 232 pharmaceutical-ingredient tariffs threaten overseas supply costs and clinical timelines
- Most material clinical update: envu Phase 2b SLE trial failed primary and secondary endpoints in September 2026
- Regulatory risk: EU Pharma Package could reduce data protection and facilitate earlier generic or biosimilar entry after anticipated 2028 implementation
- Financial risk: $431.3 million liquidity insufficient for at least 12 months, with $94.9 million quarterly net loss
- Commercial risk: envu faces approved and late-stage oral competitors across psoriasis and systemic lupus erythematosus indications
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ALUMIS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.